Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 20451W101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
RTW Investments, LP
13G/A
Amendment 2
|
9.9% |
5/15/2026
Event 3/31/2026
|
|
| RTW Investments, LP | 9.9% | ||
| Roderick Wong | 9.9% | ||
| AtaiBeckley Inc. 13D/A Amendment 6 | 4.96% |
2/17/2026
Event 1/21/2026
|
|
|
Vivo Opportunity Fund Holdings, L.P.
13G/A
Amendment 2
|
3.2% |
11/14/2025
Event 9/30/2025
|
|
| Vivo Opportunity Fund Holdings, L.P. | 3.2% | ||
| Vivo Opportunity, LLC | 3.2% | ||
| Vivo Opportunity Cayman Fund, L.P. | 0.2% | ||
| Vivo Opportunity Cayman, LLC | 0.2% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
3.6% |
11/14/2025
Event 9/30/2025
|
|
| Nantahala Capital Management, LLC | 3.6% | ||
| Wilmot B. Harkey | 3.6% | ||
| Daniel Mack | 3.6% | ||
|
ATAI Life Sciences N.V.
13D/A
Amendment 5
|
6.0% |
10/29/2025
Event 10/27/2025
|
|
| ATAI Life Sciences N.V. | 6.0% | ||
| ATAI Life Sciences GmbH (formerly ATAI Life Sciences AG) | 0% | ||
|
RTW Investments, LP
13G/A
Amendment 1
|
9.9% |
8/14/2025
Event 6/30/2025
|
|
| RTW Investments, LP | 9.9% | ||
| Roderick Wong | 9.9% | ||
|
RTW Investments, LP
13G/A
Amendment 1
|
0% |
8/14/2025
Event 6/30/2025
|
|
| RTW Investments, LP | 0% | ||
| Roderick Wong | 0% | ||
|
RTW Investments, LP
13G/A
Amendment 1
|
9.9% |
8/14/2025
Event 6/30/2025
|
|
| RTW Investments, LP | 9.9% | ||
| Roderick Wong | 9.9% | ||
|
Nantahala Capital Management, LLC
13G
|
6.2% |
8/14/2025
Event 6/30/2025
|
|
| Nantahala Capital Management, LLC | 6.2% | ||
| Wilmot B. Harkey | 6.2% | ||
| Daniel Mack | 6.2% | ||
|
TCG Crossover GP I, LLC
13G/A
Amendment 1
|
3.9% |
8/14/2025
Event 6/30/2025
|
|
| TCG Crossover GP I, LLC | 1.0% | ||
| TCG Crossover Fund I, L.P. | 1.0% | ||
| TCG Crossover GP II, LLC | 2.9% | ||
| TCG Crossover Fund II, L.P. | 2.9% | ||
| Chen Yu | 3.9% | ||
|
Vivo Opportunity Fund Holdings, L.P.
13G/A
Amendment 1
|
6.6% |
5/15/2025
Event 3/31/2025
|
|
| Vivo Opportunity Fund Holdings, L.P. | 6.6% | ||
| Vivo Opportunity, LLC | 6.6% | ||
| Vivo Opportunity Cayman Fund, L.P. | 0.4% | ||
| Vivo Opportunity Cayman, LLC | 0.4% | ||
|
RTW Investments, LP
13G
|
8.3% |
5/15/2025
Event 3/31/2025
|
|
| RTW Investments, LP | 8.3% | ||
| Roderick Wong, M.D. | 8.3% | ||
|
Integrated Core Strategies (US) LLC
13G/A
Amendment 2
|
3.0% |
5/7/2025
Event 3/31/2025
|
|
| Integrated Core Strategies (US) LLC | 2.1% | ||
| Millennium Management LLC | 3.0% | ||
| Millennium Group Management LLC | 3.0% | ||
| Israel A. Englander | 3.0% | ||
|
George Jay Goldsmith
13G/A
Amendment 4
|
2.4% |
4/15/2025
Event 3/31/2025
|
|
| George Jay Goldsmith | 2.4% | ||
| Ekaterina Malievskaia | 2.3% | ||
|
ATAI Life Sciences N.V.
13D/A
Amendment 4
|
7.5% |
3/5/2025
Event 3/5/2025
|
|
| ATAI Life Sciences N.V. | 7.5% | ||
| ATAI Life Sciences AG | 7.5% | ||
|
Citadel Advisors LLC
13G/A
Amendment 1
|
1.7% |
2/14/2025
Event 12/31/2024
|
|
| Citadel Advisors LLC | 1.3% | ||
| Citadel Advisors Holdings LP | 1.3% | ||
| Citadel GP LLC | 1.3% | ||
| Citadel Securities LLC | 0.4% | ||
| Citadel Securities Group LP | 0.4% | ||
| Citadel Securities GP LLC | 0.4% | ||
| Kenneth Griffin | 1.7% | ||
|
George Jay Goldsmith
13G/A
Amendment 3
|
2.6% |
2/13/2025
Event 12/31/2024
|
|
| George Jay Goldsmith | 2.6% | ||
| Ekaterina Malievskaia | 2.5% | ||
|
Integrated Core Strategies (US) LLC
13G/A
Amendment 1
|
3.7% |
2/6/2025
Event 12/31/2024
|
|
| Integrated Core Strategies (US) LLC | 3.4% | ||
| Millennium Management LLC | 3.7% | ||
| Millennium Group Management LLC | 3.7% | ||
| Israel A. Englander | 3.7% | ||
|
Deep Track Capital, LP
13G
|
10.0% |
1/17/2025
Event 1/10/2025
|
|
| Deep Track Capital, LP | 10.0% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 10.0% | ||
| David Kroin | 10.0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 6 | 33.7 k | $418 k |
| 2026 Q2 | 246 | 91.4 M | $1.29 B |
| 2026 Q1 | 212 | 93.3 M | $516 M |
| 2025 Q4 | 185 | 55.0 M | $380 M |
| 2025 Q3 | 177 | 55.5 M | $318 M |
| 2025 Q2 | 159 | 52.4 M | $147 M |
| 2025 Q1 | 145 | 51.9 M | $148 M |
| 2024 Q4 | 140 | 30.9 M | $117 M |
| 2024 Q3 | 143 | 32.8 M | $206 M |
| 2024 Q2 | 137 | 29.8 M | $180 M |
| 2024 Q1 | 130 | 27.5 M | $229 M |
| 2023 Q4 | 143 | 23.1 M | $202 M |
| 2023 Q3 | 128 | 22.3 M | $166 M |
| 2023 Q2 | 111 | 8.30 M | $68.7 M |
| 2023 Q1 | 115 | 8.18 M | $81.3 M |
| 2022 Q4 | 122 | 7.62 M | $61.2 M |
| 2022 Q3 | 130 | 7.49 M | $83.6 M |
| 2022 Q2 | 119 | 6.83 M | $77.8 M |
| 2022 Q1 | 124 | 7.93 M | $106 M |
| 2021 Q4 | 148 | 7.85 M | $173 M |
| 2021 Q3 | 137 | 7.64 M | $229 M |
| 2021 Q2 | 121 | 7.73 M | $295 M |
| 2021 Q1 | 94 | 5.75 M | $212 M |
| 2020 Q4 | 72 | 5.99 M | $314 M |
| 2020 Q3 | 40 | 5.49 M | $192 M |
| 2020 Q2 | 1 | 1.00 k | $38.0 k |
| 2020 Q1 | 1 | 1.00 k | $38.0 k |
| 2019 Q4 | 1 | 1.00 k | $38.0 k |
| 2019 Q3 | 1 | 1.00 k | $38.0 k |
| 2019 Q2 | 1 | 1.00 k | $38.0 k |
| 2019 Q1 | 1 | 1.00 k | $38.0 k |